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South African HIV-1 subtype C 
transmitted variants with a specific V2 
motif show higher dependence on α4β7 
for replication
Simone I Richardson1,2, Elin S Gray1,7, Nonhlanhla N Mkhize1,2, Daniel J Sheward3, Bronwen E Lambson1,2, 
Constantinos Kurt Wibmer1,2, Lindi Masson3, Lise Werner4, Nigel Garrett4, Jo‑Ann S Passmore3,4,5, 
Quarraisha Abdool Karim4, Salim S Abdool Karim4,6, Carolyn Williamson3,4,5, Penny L Moore1,2,4  
and Lynn Morris1,2,4*
Abstract 
Background: The integrin α4β7 mediates the trafficking of immune cells to the gut associated lymphoid tissue 
(GALT) and is an attachment factor for the HIV gp120 envelope glycoprotein. We developed a viral replication inhibi‑
tion assay to more clearly evaluate the role of α4β7 in HIV infection and the contribution of viral and host factors.
Results: Replication of 60 HIV‑1 subtype C viruses collected over time from 11 individuals in the CAPRISA cohort 
were partially inhibited by antibodies targeting α4β7. However, dependence on α4β7 for replication varied substan‑
tially among viral isolates from different individuals as well as over time in some individuals. Among 8 transmitted/
founder (T/F) viruses, α4β7 reactivity was highest for viruses having P/SDI/V tri‑peptide binding motifs. Mutation of T/F 
viruses that had LDI/L motifs to P/SDI/V resulted in greater α4β7 reactivity, whereas mutating P/SDI/V to LDI/L motifs 
was associated with reduced α4β7 binding. P/SDI/V motifs were more common among South African HIV subtype C 
viruses (35%) compared to subtype C viruses from other regions of Africa (<8%) and to other subtypes, due in part to 
a founder effect. In addition, individuals with bacterial vaginosis (BV) and who had higher concentrations of IL‑7, IL‑8 
and IL‑1α in the genital tract had T/F viruses with higher α4β7 dependence for replication, suggesting that viruses 
with P/SDI/V motifs may be preferentially transmitted in the presence of BV in this population.
Conclusions: Collectively, these data suggest a role for α4β7 in HIV infection that is influenced by both viral and host 
factors including the sequence of the α4β7 binding motif, the cytokine milieu and BV in the genital tract. The higher 
frequency of P/SDI/V sequences among South African HIV‑1 subtype C viruses may have particular significance for the 
role of α4β7 in this geographical region.
Keywords: HIV entry, α4β7, Tripeptide‑binding motif, Bacterial vaginosis, Cytokines
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The primary site of HIV replication following infection is 
the gut associated lymphoid tissue (GALT) [1, 2]. In order 
to migrate to the GALT and other tissues, leukocytes 
engage with adhesion molecules expressed on the surface 
of vascular endothelial cells. One of these receptors is the 
integrin α4β7 that binds to monomeric gp120 [3]. Since 
the genital mucosa does not contain organised immune-
inductive sites, it relies on α4β7+ T cells to traffic from 
other sites including the Peyer’s patches [4]. Therefore, 
the ability of α4β7+ T cells to home to secondary lym-
phoid tissues and the GALT [5, 6], coupled with their 
presence at the site of sexual transmission of HIV [7, 8] 
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and co-expression with multiple HIV susceptibility mark-
ers [9], suggests that the initial and most relevant site for 
the gp120-α4β7 interaction is the genital mucosa.
The natural ligands of α4β7 (MAdCAM-1, VCAM-1 
and fibronectin [10]) all bind through structurally homol-
ogous binding motifs that comprise three residues with 
a central aspartic acid; Leu-Asp-Thr (LDT), Ile-Asp-Ser 
(IDS) and Leu-Asp-Val (LDV), respectively [11]. The 
principal contact sites for these natural ligands are pre-
sent on the α4-chain [12]. By blocking α4β7 activity with 
inhibitory antibodies [13], Arthos et  al. showed that 
gp120 binds to α4β7 in a manner that mimics the natural 
ligands [3]. The V2 domain of gp120 contains a similar 
tri-peptide motif at position 179–181 (HXB2 number-
ing) with the aspartic residue at position 180 being 98% 
conserved across all HIV isolates [3, 14]. The ITGA4 gene 
that encodes the α4 subunit shows no polymorphisms 
in humans and did not correlate with HIV transmission 
or disease progression [15]. Nevertheless, there appears 
to be significant variation in the levels of α4β7 reactivity 
among viruses from different individuals [3]. This sug-
gests that it is the contact residues in gp120 that influ-
ence α4β7 affinity. This is bolstered by data that showed 
differences in the sequence of the α4β7 tri-peptide motif 
were linked to the differential dissemination potential of 
distinct HIV-1 genetic forms in China [16]. Recently, Tas-
saneetrithep et  al. described a tri-peptide sequence just 
upstream of the α4β7 motif as a determinant of integrin 
binding [17], suggesting that additional viral properties 
play a role in reactivity with α4β7.
Although gp120 binds α4β7 this interaction is not 
essential for viral entry, unlike CD4 and CCR5 [3]. 
Rather, α4β7 is thought to act as an attachment factor, 
offering a selective advantage for HIV entry by lowering 
the entropic barrier that slows the ligation of envelope 
spikes to CD4 and CCR5 [18]. Thus, the gp120–α4β7 
interaction may be particularly important during the ear-
liest stages of HIV infection. CD4+ T cells expressing 
high levels of α4β7 are more susceptible to HIV-1 infec-
tion partly because this subset also expresses high levels 
of CCR5 [9]. This phenotype extends to sites of initial 
HIV infection such as blood, rectum, colon and genital 
mucosa of the female reproductive tract [7–9]. However, 
other studies have failed to confirm any impact of α4β7 
on replication in vitro [19–21]. Despite this controversy, 
when healthy macaques were treated with an anti-α4β7 
mAb (Act-1), they were protected from transmission by 
low-dose SIVmac251 challenge [22]. This antibody also 
reduced viremia and proviral DNA in the GALT in a high 
dose challenge model although it did not extend to pro-
tection [23]. In addition, a recent study has shown that 
the number of α4β7+ CD4+ T cells at the site of rectal 
transmission is a risk factor for productive HIV infection 
in rhesus macaques [24]. Sexually transmitted infections 
such as HSV-2 have also been shown to increase expres-
sion levels of α4β7+ and enhance the risk for vaginal 
SHIV infection [25].
To further clarify the role for α4β7 in HIV infection, 
we made use of longitudinal viruses from the CAPRISA 
Acute Infection cohort based in Durban, South Africa, 
a region with one of the highest HIV incidence rates in 
the world [26]. We devised an α4β7-inhibition replica-
tion assay and tested dependence of the viruses on α4β7 
for entry and replication using inhibitory mAbs. Here we 
show that variation in the α4β7 binding motif influences 
T/F virus α4β7-dependent replication. Furthermore, the 
immune environment in the genital mucosa at the time 
of HIV infection correlated with the transmission of 
particular binding motifs which are highly prevalent in 
South African subtype C viruses.
Results
α4β7 expressed on 293T cells binds infectious HIV
While monomeric gp120 has been shown to bind α4β7 
[3], we sought to determine whether biologically relevant 
forms of HIV envelope expressed on the viral mem-
brane, also bound the integrin. For this, plasmids encod-
ing human α4 and β7 subunits were co-transfected and 
expressed in 293T cells (which do not express any HIV 
receptors) and stained with CD49d (α4)-PE (targeting an 
epitope on α4 overlapping the region of gp120 binding) 
and β7-FITC to confirm co-expression (Additional file 1, 
panel A). These cells were used in a direct binding assay, 
where HIV bound to α4β7 was detected by p24-FITC 
(Additional file 1, panels B and C). These cells were also 
used in a competition binding assay, where a reduction of 
CD49d (α4)-PE binding was measured relative to α4β7+ 
cells incubated without virus or the inhibitory mAbs, 
HP2/1 (anti-α4 mAb) and Act-1 (anti-α4β7 mAb). Two 
types of infectious viruses were used for these experi-
ments; infectious molecular clones (IMCs) which com-
prised the entire proviral genome of isolates of interest 
and infectious envelope clones (IECs) which made use 
of a common pNL4-3 delta Env backbone co-transfected 
with different gp160 genes.
In agreement with published studies, SF162 was shown 
to bind to α4β7-expressing cells in a direct binding assay 
[3, 19] (Figure 1a). No significant differences were noted 
between the SF162 IMC or IEC in either of the binding 
assays or between another two IMC/IEC pairs used in this 
study (CAP210 and CAP239) (Additional file  2). Similar 
to what was shown previously (using monomeric gp120) 
[27], the CAP88 T/F IEC bound better to α4β7 expressed 
on 293T cells than the CAP88 12 month IEC (Figure 1a). 
These findings were confirmed in a competition assay 
where the CAP88 T/F was better able to compete for 
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integrin binding with fluorescently labelled α4β7-directed 
mAbs than the 12 month IEC (*p = 0.018; paired t test), 
although not as efficiently as the inhibitory mAbs (Fig-
ure  1b). These data confirm the capacity of biologically 
relevant cell surface-expressed HIV-1 Env to bind α4β7.
Anti‑α4β7 antibodies partially inhibit virus replication
We next determined whether binding to α4β7 enhanced 
HIV infection of primary CD4+ T cells induced to 
express α4β7 using all-trans retinoic acid (ATRA), the 
effect of which was measured by flow cytometry (Addi-
tional file  3). For this, we developed an α4β7 inhibition 
replication assay which measured viral replication (levels 
of p24) in ATRA-treated CD4+ T cells in the presence 
of HP2/1 or Act-1 mAbs over a 10 days period. Accurate 
titration of the inhibitory mAbs was crucial as saturating 
concentrations were shown to enhance viral replication 
in this assay (Additional file 4). This effect is likely to be 
Figure 1 HIV binding to cell‑surface expressed α4β7. a Direct binding of SF162 (left panel) and CAP88 (right panel) viruses to α4β7 expressed on 
293T cells measured by p24‑FITC staining. For SF162, both the IEC and IMC (solid and dashed black lines respectively) bound α4β7 at similar levels 
which were higher than the untransfected α4β7− 293T cells (grey line). The IEC of CAP88 T/F (solid black line) bound better than CAP88 12M (dashed 
black line). This is representative of 3 independent experiments. b Competition assay where CAP88 T/F (black dashed) bound to the integrin is 
measured as a decrease in α4‑PE antibody binding relative to unbound α4β7 transfected 293T cells (black solid). HP2/1 and Act‑1 binding in the 
absence of virus were used as positive controls (red and blue respectively) while the negative control was untransfected cells incubated with virus. 
Results are representative of four independent experiments. The CAP88 T/F virus bound significantly better to the α4β7 integrin compared to the 
12 month IEC in the competition binding assay as shown in the bar graph (p = 0.018; paired t test). Bars represent the mean binding percentage of 
three independent experiments and the error bars represent the SEM.
Page 4 of 16Richardson et al. Retrovirology  (2015) 12:54 
the result of signalling processes and homotypic cluster-
ing of cells enhanced by ligands to and antibodies against 
α4β7 [12, 19, 28]. This titration is unique to this study and 
may have allowed us to develop an assay in which we see 
consistent partial inhibition of replication by the inhibi-
tory mAbs, in contrast to other studies [19, 21]. The opti-
mal mAb concentration for viral inhibition by HP2/1 was 
0.275 nM and for Act-1 was 2.2 pM which were used in 
all subsequent experiments.
A total of 60 IECs from 11 CAPRISA participants were 
tested in this assay to determine if the α4β7 receptor 
was commonly used by HIV. While replicative capac-
ity differed among IECs, all showed lower levels of rep-
lication (range 15–88%) in the presence of antibodies to 
α4β7, confirming usage of the integrin (Additional file 5). 
There was no difference in replication inhibition levels 
between HP2/1 and Act-1, suggesting that the inhibition 
was a result of blocking the heterodimeric α4β7 surface 
molecule (Figure  2a). Treatment with anti-α4β7 mAbs 
resulted in only partial inhibition of replication, com-
pared to an anti-CD4 mAb that resulted in complete 
abrogation of replication of all viruses consistent with its 
essential role in viral entry. These data re-enforce previ-
ous findings that α4β7 serves as an attachment factor and 
unlike CD4 and CCR5, is not essential for HIV infection 
[3, 19, 21, 29].
The dependence on α4β7 for viral replication changes 
over time
In order to assess whether the dependence on α4β7 var-
ied over the course of HIV infection, we selected three 
participants who had a complete longitudinal set of IECs, 
including the T/F virus and viruses from shortly after 
infection (1 or 2  months post-infection) as well as later 
time points up to 3 years post-infection. All 3 individu-
als showed a similar pattern, with the T/F virus having a 
greater dependence on α4β7 for replication than viruses 
from 1 to 2  months (CAP88, CAP200 and CAP206; 
p  <  0.001, p  <  0.01 and p  <  0.001 respectively using a 
repeated measures ANOVA) (Figure 2b). However, α4β7 
dependence of viruses from later time points was not 
significantly different from T/F viruses. Longitudinal 
Figure 2 HIV dependence on α4β7 for replication over the course of infection. a Kinetic growth curves of IECs from CAP88 T/F, 1 month, 12 and 
39 months post‑infection (green lines) in the presence of α4β7 inhibitory mAbs Act‑1 (blue) and HP2/1 (red) or anti‑CD4 mAb (purple) measured 
as p24 (ng/ml) over 10 days. Inhibition by Act‑1 and HP2/1 was partial at the point of exponential growth of the virus control and did not differ 
between the two mAbs. Curves are representative of three independent experiments, each one in triplicate and error bars representative of SEM. 
b Longitudinal IECs (from 3 individuals) including the T/F virus and multiple 2–39 months post‑infection viruses were tested for their dependence 
on α4β7 for viral replication. The percentage inhibition by HP2/1 (red) and Act‑1 (blue) is expressed as the difference in p24 concentration between 
HP2/1 or Act‑1 treated and untreated cells at the point of exponential viral growth. Differences in dependence across all time points in each of 
these three individuals were significant by a repeated measures ANOVA (p < 0.0001) as well as between CAP88 T/F and 1 month p.i, (**p < 0.001) 
CAP200 T/F and 6 months p.i. (*p < 0.01) and CAP206 T/F and 2 months p.i (**p < 0.001). Pairwise comparisons were adjusted by the Tukey method. 
Bars represent means of between two and three independent experiments with the error bars indicating SEM.
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samples from additional CAPRISA participants showed a 
similar trend, but this analysis was limited because clones 
from either the T/F or later time-points were not avail-
able (Additional file 5). We found no association between 
dependence on α4β7 and markers of disease progression 
such as CD4 counts or viral loads when corrected for 
duration of infection (data not shown).
Analysis of longitudinal sequences revealed no changes 
in the α4β7 tri-peptide motif in CAP88 and CAP206 
while in CAP200 there was a change from SDV to PDI 
by 6  months post infection, but this was due to dual 
infection (Sheward, unpublished) (Additional file 6). For 
CAP88, there were only three amino acid differences 
between the T/F and the 2 month clone; L568R, a highly 
conserved residue in the N-heptad repeat of gp41 and 
two changes in the cytoplasmic tail. For the CAP206 pair 
there was an introduction of a predicted N-linked glycan 
(PNG) at position 462 in V5 and a D474N mutation in 
the C5 region (Additional file 7). CAP200 showed a total 
of 39 non-synonymous changes in envelope at 6 months 
Overall, no common sequence signature was associ-
ated with changes in α4β7 reactivity among these three 
participants.
Since decreased loop length and PNG density of the 
gp120 V1/V2 and C3/V4 regions have previously been 
shown to correlate with increased α4β7 binding [27], 
we analysed these features among all 60 clones. We 
found that α4β7 dependence positively correlated with 
the length and predicted glycan density of V1/V2 which 
includes the α4β7 binding site and negatively correlated 
with C3/V4 length, however these associations were only 
weakly supported (Additional file  8, panel A). We also 
compared individual predicted glycan sites (excluding 
those in variable regions which could not be accurately 
aligned) across all 60 sequences (Additional file 8, panel 
B). Viruses with high α4β7 dependence had significantly 
higher frequencies of PNG234 (p = 0.009) and PNG334 
(p = 0.006), while PNG332 (p = 0.026) was present less 
frequently as compared by the Fisher exact test. These 
data suggest that specific glycans may play a role in α4β7 
dependence but it is likely that additional factors influ-
ence interactions with the integrin.
Impact of host factors at transmission on α4β7 
dependence for replication
Since the role of α4β7 is likely to be most relevant at 
transmission, we focused on the 8 T/F viruses included 
in this study. These exhibited a wide range of Act-1 inhi-
bition (22–69%) indicating that high α4β7 dependence is 
not a typical feature of T/F viruses (Figure 3a). We inves-
tigated if this variation could be explained by host fac-
tors present at the time of transmission. STIs have been 
identified as a major cause of inflammatory cytokine 
upregulation and immune cell recruitment to the genital 
mucosa, in some cases typified by the homing function 
of α4β7 [7, 30]. Given this and the integrin’s role in sup-
porting HIV replication, we considered whether these 
factors could create an environment conducive for α4β7 
interaction. Only Trichomonas vaginalis, Chlamydia tra-
chomatis and bacterial vaginosis (BV) were detected in 
some individuals at the time of transmission. Strikingly, 
individuals with BV (Nugent scores ≥7) had viruses with 
significantly higher dependence on α4β7 than those who 
did not (61.58 vs. 29.64% α4β7 dependence; p  =  0.029 
Mann–Whitney test) (Figure 3b).
Next, we investigated the cytokine milieu in the geni-
tal compartment at the time point when the T/F viruses 
were isolated. The concentrations of interleukin (IL)-7 
(r2 = 0.89), IL-8 (r2 = 0.78) and IL-1α (r2 = 0.86) in cer-
vicovaginal lavages (CVLs) correlated significantly with 
α4β7 dependence in a univariate analysis (p  =  0.007, 
p = 0.038, p = 0.013 respectively by Spearman’s correla-
tion) but this was lost when the p-values were adjusted 
for multiple comparisons, likely a result of the small 
sample size (Figure 3c; Additional file 9). These associa-
tions were not mirrored in plasma where only eotaxin, an 
eosinophil chemoattractant whose function is mediated 
by α4β7 [31], showed a significant univariate correlation 
(p  =  0.031; r2  =  0.80) but a non-significant adjusted p 
value of 0.899.
The sequence of the α4β7‑binding motif influences virus 
binding and replication
While the aspartic acid in the tri-peptide binding motif 
in the V2 domain is highly conserved, there is variation at 
the first and third amino acid residues. Interestingly, the 
sequence of the tri-peptide α4β7 binding motifs could 
be used to stratify the 8 T/F viruses based on replication 
dependence (Figure 4a). The 4 T/F viruses with high α4β7 
reactivity had P/SDI/V motifs while the 4 T/F viruses 
with low α4β7 reactivity had LDI/L motifs (p  =  0.029, 
Mann–Whitney test).
To determine if the sequence of the motif impacted 
on binding to α4β7, we mutated the tri-peptide motif 
from P/SDI/V to LDI/L (or vice versa) in 5 of the 8 T/F 
viruses. The α4β7 binding motif of the CAP8 T/F virus 
(which showed low α4β7 dependence) was mutated from 
LDI to PDI. Similarly the CAP256 T/F was mutated from 
LDL to SDI. In both cases, mutated viruses had signifi-
cantly increased α4β7 dependence (p  =  0.02, paired t 
test, Figure 4b). Furthermore, binding to the integrin as 
measured by the direct p24 binding assay was enhanced 
when motifs were mutated from LDI/L to P/SDI (Fig-
ure  4c). Notably, when viral motifs were mutated from 
P/SDI to LDI/L, none of the mutated viruses were able 
to replicate.
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Analysis of the α4β7 binding motif, presence of BV and the 
genital and plasma cytokine milieu in the CAPRISA 002 
cohort
To further examine the host and viral factors associ-
ated with α4β7 dependence, we analysed additional 
women in the CAPRISA 002 cohort where STI, 
cytokine and sequence data were available. Of the 30 
women who had STI clinical information, 18 were 
infected with viruses with P/SDI/V and 12 with LDI/L 
motifs. In this larger analysis, BV diagnosis (Nugent 
score ≥7) was significantly associated with viruses 
having P/SDI/V motifs (17/18 P/SDI/V motifs vs 7/12 
LDI/L motifs; p = 0.026, Fisher exact test) (Figure 5a), 
mirroring what was seen in the smaller sub-group of 
8 women. Using available cytokine concentrations for 
CVL (n = 25 women) and plasma (n = 28 women), we 
investigated the relationship with different viral motifs 
in each compartment. CVL exhibited a dramatically 
different association profile to plasma (Figure  5b). In 
CVL, IL-17 showed the strongest positive associa-
tion with the P/SDI/V motif and IL-10 the strongest 
inverse correlation, although these did not correlate 
with α4β7 dependence (Additional file 9). Of the three 
cytokines in CVL (IL-7, IL-8 and IL-1α) that were pre-
viously shown to correlate with α4β7 dependence for 
replication (Figure  3c), IL-7 and IL-8 concentrations 
were 2- to 5-fold higher in CVL from women who were 
infected with viruses containing P/SDI/V motifs com-
pared to women without these motifs in agreement 
with the original observation.
Figure 3 Bacterial vaginosis and genital cytokines associated with α4β7‑dependent T/F viruses. a T/F viruses of CAP225, CAP88, CAP200 and 
CAP206 showed high (>50%, indicated by the dotted line) α4β7 dependence (green) while the remaining four showed lower α4β7 dependence 
(blue). Dependence on α4β7 was determined using Act‑1 mAb inhibition. Bars represent the mean of four independent experiments, with error bars 
indicating SEM. b Individuals infected with T/F viruses that had higher dependence on α4β7 were significantly more likely to be BV positive at the 
time of infection (p = 0.029; Mann–Whitney test). c Concentrations of cytokines in CVL (n = 31) and plasma (n = 30) were determined and cor‑
related with T/F virus dependence on α4β7 for replication. IL‑7, IL‑8 and IL‑1α showed significant univariate correlations in the CVL. In contrast only 
eotaxin was significantly associated in plasma (shown in the grey boxes) while IL‑8, IL‑1α and IL‑7 showed no correlation in plasma. No significance 
was maintained at a multivariate level. Relevant p values and Spearman’s coefficients are shown where *p < 0.05.
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South African HIV‑1 subtype C viruses show a higher 
frequency of P/SDI/V motifs
Among the 42 women where viral sequence data was 
available, 20 (48%) were infected with viruses that con-
tained P/SDI/V motifs, exceeding those with LDI/V/L 
motifs (n = 14; 33%) (Figure 5c). To explore whether this 
was typical of global viruses, we analysed ~4,700 unique 
V1/V2 sequences from the Los Alamos National Labora-
tory (LANL) HIV database with information on genetic 
subtype, route of transmission, sex of individual and 
region. HIV-1 subtype C showed the highest prevalence 
of viruses with P/SDI/V motifs (18%), in contrast to sub-
types A, B and D (2, 3 and 8% P/SDI/V motifs respec-
tively). When subtype C sequences were broken down by 
region, however, the increased frequency of the P/SDI/V 
motif was almost completely accounted for by South 
African viruses. Of 781 sequences from South Africa, 
excluding sequences from the CAPRISA 002 cohort, 273 
(35%) had the P/SDI/V motif. This is in contrast to other 
regions where subtype C circulates, including Tanzania, 
Figure 4 Viruses with P/SDI/V α4β7 binding motifs are more reactive with the integrin. a T/F viruses with P/SDI/V showed a higher dependence 
on the integrin compared to those with LDI/L motifs (n = 4, blue) (*p = 0.029; Mann–Whitney test). b Mutation of CAP8 T/F from LDI to PDI and 
CAP256 T/F from LDL to SDI resulted in a significant increase in α4β7 dependence (*p = 0.02 for both, paired t test). Bars represent three independ‑
ent experiments and error bars indicate the SEM. c CAP8 and CAP256 mutants also showed increased α4β7 binding compared to the wild‑type in 
the direct assay using p24‑FITC MFI as a read‑out, representative of three independent experiments.
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Malawi, Botswana and Zambia where the frequency of 
the P/SDI/V motif was less than 8%. Since many South 
African sequences were from women and the route of 
transmission is predominantly heterosexual, we com-
pared gender and transmission route across all sequences 
in the database. However, no significant differences were 
noted between the groups (not shown).
When the phylogeny of full-length subtype C gp160 
sequences (n  =  776) was examined the enrichment of 
non-LDI/L motifs in South African sequences (indi-
cated by the dotted lines) was found to be due to founder 
effects (Figure  5d). Two distinct South African lineages 
with founders that had PDI motifs with branch support 
of 0.955 and 0.999 were identified. These data suggest 
that the high frequency of P/SDI/V motifs is not typical 
of subtype C viruses in general, but rather represents a 
signature of South African subtype C viruses.
Discussion
While it is generally accepted that gp120 binds α4β7 
via a tri-peptide motif in V2, its role in HIV infection 
is controversial [19–21, 27, 29]. Using viruses from the 
well-characterized CAPRISA acute infection cohort, we 
were able to show that interaction with α4β7 was com-
mon but highly variable between isolates from different 
individuals as well as within an individual over time. Fur-
thermore, T/F viruses with a P/SDI/V tri-peptide motif 
bound α4β7 more efficiently and had higher dependence 
on α4β7 for replication compared to those with an LDI/V 
motif. Notably, the P/SDI/V genotype was more common 
among South African subtype C viruses. The dispropor-
tionate distribution of P/SDI/V genotypes in the South 
African-based CAPRISA cohort may in part explain why 
this study has enabled us to more clearly define a role for 
α4β7 in HIV infection.
Our study used infectious viruses from the same indi-
viduals over multiple time points, and to our knowledge, 
includes the largest collection of T/F viruses investigated 
for α4β7 dependence linked to extensive clinical and labo-
ratory data. For those individuals where we had complete 
longitudinal datasets (CAP88, CAP200 and CAP206), we 
found α4β7 dependence was high for the T/F viruses but 
decreased during acute infection. However, high depend-
ence on α4β7 was not a feature common to all T/F viruses 
and is therefore unlikely to be a transmission signature. 
The loss of high reactivity also coincides with migration 
to the target tissue after which α4β7 would no longer pro-
vide any selective advantage [32]. Many of the chronic 
viruses tested also had high α4β7 dependence but its role 
at this stage of infection is less clear. Comparison of the 
longitudinal sequences from these 3 participants revealed 
no changes in the α4β7 binding motif except for CAP200, 
who was dually-infected. However, we noted changes in 
other regions such as V5 and gp41. Glycan changes in V5, 
that forms part of the conformational epitope for CD4 
binding mAbs such as VRC01 [33] may affect α4β7 reac-
tivity as the integrin is in close proximity to CD4 on the 
cell surface [9, 34]. Similarly, changes in gp41 may impact 
on membrane fusion and viral incorporation, with one of 
the changes, L568R, associated with a reduction in the 
ability of HIV-1 envelope protein expressing cells to fuse 
with target cells [34]. Regardless, the absence of common 
changes between the T/F and acute/early viruses in V1/V2 
suggests that regions outside this domain influence α4β7 
reactivity. We did find that α4β7 dependence was weakly 
associated with higher glycan density and longer V1/V2 
loops. This is at odds with Nawaz et al. [27], although both 
studies found that shorter C3/V4 domain lengths was 
associated with increased α4β7 binding affinity. In addi-
tion to this, we found the presence or absence of specific 
glycans correlated with α4β7 reactivity. The under-repre-
sentation of PNG332 in viruses with high α4β7 depend-
ence and the reciprocal overrepresentation of PNG334 is 
intriguing as the 332 glycan has been found to occur less 
frequently in T/F viruses [35]. These findings suggest that 
while differences in predicted glycan occupancy alone 
cannot explain α4β7 reactivity, their position may impact 
the ability of the tri-peptide motif to access α4β7 on the 
cell surface. Recent data suggests that the tri-peptide 
motif is occluded in the pre-fusion trimer structure [36], 
however this crystalline structure does not account for 
the significant flexibility and entropy associated with the 
(see figure on next page)
Figure 5 Viruses with P/SDI/V motifs are associated with BV and are more frequent among South Africa subtype C viruses. a P/SDI/V α4β7 binding 
motifs were significantly associated with concurrent BV infection as compared to those with LDI/L motifs (17/18 P/SDI/V motifs vs. 7/12 LDI/L motifs; 
*p = 0.026, Fisher exact test). b Fold differences of mean cytokine levels in CVL and plasma among 25 and 28 individuals respectively in the CAPRISA 
002 cohort separated based on those that have P/SDI/V motifs (green, n = 15 and n = 17) and those that have LDI/L motifs (blue, n = 10 and n = 11). 
The intensity of the respective colours is indicative of the fold differences between the two groups (green = greater fold difference in P/SDI/V group; 
blue = greater fold difference in LDI/L group) which is ranked based on the CVL profile. c Global frequency of the P/SDI/V motif (green), LDI/V/L 
motif (blue) and other motifs (grey) among sequences from subtypes A, B, C and D from the Los Alamos database. Further breakdown of subtype C 
sequences according to the country of origin is shown in the box. Viruses from South Africa showed the highest frequency of P/SDI/V motifs (35%) 
with those from the CAPRISA 002 cohort exceeding this (48%; n = 20). d A maximum likelihood tree inferred using Fasttree of all subtype C gp160 
sequences from the LANL database (n = 776) rooted on the 1959 Zaire sequence with HXB2 as an outgroup. Nodes are coloured according to the 
α4β7 binding motif (positions 179–181), South African sequences indicated by dotted lines and CAPRISA sequences indicated by red lines.
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variable domains of gp120 in which transient exposure of 
the α4β7 binding site is plausible. Non-functional trim-
ers on the surface of HIV could also provide additional 
opportunities for viral particles to bind α4β7 [37].
STIs have been identified as a major cause of inflamma-
tory cytokine upregulation and immune cell recruitment to 
the genital mucosa [38] increasing HIV risk [39–41]. Both 
HSV-2 and Chlamydia trachomatis infection increase the 
number of α4β7+ CD4+ T cells in the genital tissue [7, 30, 
42]. Bacterial vaginosis, a common syndrome characterised 
by a shift in vaginal flora composition [43], has been identi-
fied as a specific risk factor for HIV acquisition, also influ-
encing genital tract cytokine concentrations [40, 44, 45]. In 
this study, we found that BV diagnosis at the time of HIV 
infection was associated with T/F viruses that had high 
α4β7 dependence for replication, but found no such asso-
ciations with STI’s. In a recent study by Masson et al., BV in 
the CAPRISA cohort upregulated inflammatory cytokines 
while downregulating chemokines in the CVL, in contrast 
to chlamydia and HSV-2 [46]. Chemokines are essential 
for the chemotaxis of effector cells, suggesting that BV may 
be associated with a reduction in target cells in the genital 
mucosa, favouring viruses with enhanced α4β7 reactivity. 
However, since the data presented here does not prove cau-
sality, it is possible that the increased α4β7 dependence is 
merely a feature of viruses transmitted in these conditions. 
This is corroborated by our observation that individuals 
infected with viruses with P/SDI/V motifs were more likely 
to have BV at the time of infection. Overall, BV-associated 
changes in the genital cytokine milieu may modulate the 
mucosal barrier favouring the transmission of viruses with 
P/SDI/V α4β7 binding motifs that have a high dependence 
on the integrin.
We also found that IL-7 levels in genital secretions at 
transmission were associated with α4β7 dependence of 
T/F viruses. Recently, Cimbro et  al. demonstrated that 
IL-7 induces expression and functional activation of 
α4β7 in vitro and in vivo [47]. The levels of IL-7 required 
to upregulate the integrin, however, are associated with 
lymphopenia; an immunological state only generated late 
in HIV infection. It is therefore unlikely that the levels 
induced in the CVL at the time of infection would be suf-
ficient to influence α4β7 expression. Interestingly, other 
cytokines upregulated by BV, such as IL-8 and IL-1α [48–
51] were also associated with α4β7 dependence in CVL, 
but not in plasma, suggesting that that the most relevant 
impact of the cytokines on α4β7 is at the site of transmis-
sion. Furthermore, all 3 cytokines were associated with 
the P/SDI/V α4β7 binding motif, further suggesting that 
BV may play a significant role in determining the level of 
α4β7 interaction at transmission.
This study is the first to fully explore the effect of dif-
ferent α4β7 sequence binding motifs on α4β7 reactivity. 
Transmitted viruses with P/SDI/V motifs, present in 
only 8% of global viruses, were associated with a higher 
dependence on α4β7 for replication and bound better to 
the integrin. LDI/L/V motifs which most closely resem-
ble those of the natural ligand MAdCAM-1 (LDT) and 
fibronectin (LDV) are more common in global sequences 
accounting for 78% of all circulating variants. In addi-
tion to the LDT motif, the integrin-binding loop of 
MAdCAM-1 contains a downstream SDT motif that is 
responsible for stabilisation of the interaction [52]. Inter-
estingly, an α4β7 antagonist containing the SDV/T motif 
was more potent than one containing an LDT motif [53]. 
This suggests that different motifs display different affini-
ties for the ligand, similar to the observation in this study 
that viruses with P/SDI/V motifs have a higher reactivity 
with α4β7 as compared to LDI/V motifs.
Unexpectedly, we found that 48% of women in the 
CAPRISA 002 cohort and 35% of all South African 
sequences had P/SDI/V motifs, significantly higher than 
what is seen in other countries where HIV-1 subtype C 
circulates. This is due in part to founder effects, with two 
South African lineages having founder viruses with a PDI 
motif. The introduction and maintenance of this motif in 
South African viruses may be as a result of an immuno-
logical feature of people in this region. α4β7 expression is 
known to be regulated by ATRA, a metabolite of vitamin 
A [54]. Vitamin A deficiency is common in the South Afri-
can population as compared to other sub-Saharan African 
countries; with 19% of pregnant women having serum reti-
nol <0.70 µmol/l, higher than Botswana, Malawi or Tanza-
nia [55]. It is therefore possible that vitamin A deficiency 
may result in decreased expression of α4β7, leading to the 
selection of viruses with a α4β7 binding motifs that have a 
greater affinity for the integrin in this population. In addi-
tion, the exact composition of the microbiota in BV has 
not been fully elucidated, and it is possible that this may 
differ from region to region; possibly creating a unique 
environment in the South African population. This data 
highlights the importance of fully characterising individual 
epidemics, even those caused by the same subtype.
Conclusions
Collectively, these data suggest a role for α4β7 in HIV 
infection that changes over time and that is impacted 
during transmission by a number of factors including 
the sequence of the α4β7 binding motif, cytokine milieu 
and BV in the genital tract. This may have particular rele-
vance for South Africa where a higher frequency of α4β7-
dependent V2 motifs were present among HIV-1 subtype 
C transmitted/founder viruses. Further understanding of 
the interaction between the virus and the integrin might 
provide additional opportunities for devising vaccine and 
therapeutic strategies.
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Methods
Ethics statement
Ethical approval was received for the CAPRISA 002 
Acute Infection Study from the University of KwaZulu-
Natal, University of Cape Town and University of Wit-
watersrand. All participants provided written informed 
consent for the CAPRISA 002 study with tacit agree-
ment to adhere to regular clinic visits and blood draws. 
Approval for this particular study was granted by the 
University of the Witwatersrand.
Study participants
Participants in the CAPRISA 002 Acute Infection cohort, 
established in 2004 [26] were derived from prospective 
cohorts of high-risk HIV negative South African women 
[46]. Clinical and laboratory monitoring including CD4 
count, viral load and testing for STIs and BV were per-
formed routinely [26, 40] on all participants at enrolment 
and regularly thereafter. Eleven participants, where cloned 
longitudinal envelopes from the transmitted/founder 
and/or acute infections were available, were selected for 
the α4β7 binding and replication studies. Participants in 
the parent CAPRISA 002 cohort with sequence (n = 42), 
laboratory-diagnosed STIs or BV (n =  28) and cytokine 
(n = 25) data were available for a larger correlates study.
Testing for STIs and BV
A gynaecological examination was performed and two vul-
vovaginal swabs were collected [40]. Swabs were screened 
for C. trachomatis, N. gonorrhoeae, M. genitalium, HSV 
and T. vaginalis by PCR. BV was diagnosed by Gram stain-
ing using Nugent’s criteria (a score ≥7 indicates BV).
Cell lines
The TZM-bl cell line engineered from CXCR4-positive 
HeLa cells to express CD4, CCR5, and a firefly lucif-
erase reporter gene (under control of the HIV-1 LTR) was 
obtained from the NIH AIDS Research and Reference Rea-
gent Program, Division of AIDS, NIAID, NIH (developed by 
Dr. John C. Kappes, and Dr. Xiaoyun Wu [56, 57]). The 293T 
cell line was obtained from Dr George Shaw (University of 
Alabama, Birmingham, AL, USA). Cell lines were cultured 
at 37°C, 5% CO2 in DMEM containing 10% heat-inactivated 
fetal bovine serum (Gibco BRL Life Technologies) with 50 
ug/ml gentamicin (Sigma) and disrupted at confluency by 
treatment with 0.25% trypsin in 1 mM EDTA (Sigma).
Isolation and stimulation of CD4+ T lymphocytes 
from whole blood
CD4+ T cells were isolated to a purity of 99% from 
healthy blood donors using RosetteSep Human CD4+ 
T cell Enrichment Cocktail (Stem Cell Technologies, 
Canada) as per the manufacturer’s protocol. Isolated cells 
were cultured with 10 µM all-trans retinoic acid (ATRA) 
(Sigma-Aldrich, MO, USA), 50  ng/ml OKT3 (anti-CD3 
antibody) (eBioscience, CA, USA) and 20 U/ml IL-2 
(Roche Applied Sciences, Germany) in RPMI media sup-
plemented with 20% heat inactivated fetal bovine serum 
for 6 days at 37°C, 5% CO2 [3]. The purity of the CD4+ 
T cell population as well as the upregulation of α4β7 
by ATRA was confirmed routinely by flow cytometry. 
Donors were designated as responders or non-respond-
ers based on whether ATRA treatment upregulated the 
α4β7+ population of lymphocytes as shown in Additional 
file 3. Only 25% of donors responded to ATRA treatment 
similar to what was shown in a study by Arthos et al. [3] 
and only these donors were used in further experiments.
Flow cytometry surface staining
Isolated CD4+ T cells from ATRA-treated responders 
were stained with optimally titrated fluorescently labelled 
antibodies: CD3 energy coupled dye (ECD Beckham 
Coulter, France), CD4-Quantum dot 605 (Invitrogen, 
Carlsbad, CA, USA), anti-human CD49d (Integrin alpha 
4) R-Phycoerythrin (PE) (eBioscience, CA, USA), anti-
human/mouse integrin β7 fluorescein isothiocyanate 
(FITC) (eBioscience, CA, USA) and Aqua Fluorescent 
Reactive Dye (Invitrogen, Molecular Probes, Carlsbad) 
in 1% BSA/PBS staining buffer in the dark for 30 min at 
4°C and fixed in 0.1% paraformaldehyde/PBS. Fluores-
cence minus one controls were used to define the gating 
strategy and compensation was done using anti-mouse 
Igκ BD CompBeads. Acquisition of all samples was per-
formed on a FACSAria (BD Biosciences) and analysis 
done on FlowJo X software (TreeStar Ashland, OR, USA).
Production of infectious viruses and pseudoviruses
Cloned HIV-1 gp160 envelope genes derived by single 
genome amplification as previously described [58] from 
selected CAPRISA participants were used to produce 
infectious virions. Mutant envelopes were generated as 
detailed in Table 1 with QuikChange Lightning Kit (Strata-
gene) and confirmed by DNA sequencing. Infectious enve-
lope clones (IECs), were generated by re-amplifying the 
gp160 env gene from the envelope plasmids and co-trans-
fecting the PCR product with the pHIVΔenvBstEllnef-
hisD backbone (a gift from Dr Daniel Kuritzkes) which 
were constructed as described elsewhere [59]. Two infec-
tious molecular clones (IMCs) which contain full proviral 
genomes derived from participants CAP210 and CAP239 
and representative of the T/F viruses were also used. The 
SF162 IMC was from David Montefiori at Duke Uni-
versity, NC. The IMC plasmids were transfected in 293T 
cells and both IECs and IMCs were incubated at 37°C, 5% 
CO2 for 72 h following which the media was changed to 
fresh DMEM with 10% FBS. After a week of incubation in 
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293T cells, 1 ml of the viral supernatant was spinoculated 
for 60 min at 1,200 g, 30°C with activated CD8+ depleted 
PBMCs at 5  ×  106 cells/ml and the spinoculation was 
repeated the next day. Viral growth was monitored by an 
in-house p24 antigen ELISA as described previously [60]. 
p24 positive cultures were expanded into T25 flasks with 
fresh CD8 depleted PBMCs and following a week of incu-
bation, the viral supernatant was removed, filtered with 
a 0.2  nm micropore filter and aliquoted for freezing at 
−70°C. All viruses inputs were titrated to a TCID50/ml of 
25 as described elsewhere [56, 57].
Sequence analysis
Full length env sequences from the CAPRISA 002 cohort 
were assembled and edited using Sequencher v.4.5 and 
Bioedit v.7.0.5.3. Number and positions of predicted 
N-linked glycans were estimated using the N-GlycoSite 
tool [61]. Variable domain lengths and relative positions 
of predicted glycans were determined with reference to 
HXB2 numbering. For relative frequency of predicted 
glycan sites, envelopes that showed α4β7 reactivity above 
the mean were defined as having high α4β7 dependence 
(n  =  33) and those with values below the mean were 
considered to have low α4β7 dependence (n =  27). The 
frequency of predicted glycans (excluding those in the 
variable regions that are difficult to align accurately) were 
expressed as a proportion of either high or low α4β7 
dependent sequences. V1/V2 sequences downloaded 
from Los Alamos National Laboratory HIV database 
were selected as single unique sequences per individual. 
These sequences were further stratified by country of 
sampling, genetic subtype, mode of transmission and 
gender of infected individual. Phylogeny of gp160 of 
subtype C viruses (n = 776) was assessed using the Shi-
modaira–Hasegawa test and Fasttree to determine a 
maximum-likelihood tree and branch support.
Flow cytometry based α4β7‑virus binding assays
α4 and β7 encoding plasmids synthesised by Origene 
(Rockville, MD, USA) were co-transfected using 4  µg 
of each plasmid into 293T cells with X-tremeGENE 
Transfection Reagent (Roche) or Polyethyleimine Max 
(Polysciences, Inc., Warrington, PA, USA) and incu-
bated at 37°C, 5% CO2 for 2  days. The transfected cells 
were removed gently with 1  mM EDTA/PBS, follow-
ing which the co-expression of α4β7 was determined by 
flow cytometric staining using CD49d (integrin α4)-PE 
(eBioscience, CA, USA) and anti-human/mouse integ-
rin β7 FITC as described above. The gating strategy was 
single (FSC-H/FSC-A), live (FSC/Aqua vital negative) 
and α4β7+ (α4-PE/β7-FITC) 293T cells. Two types of 
binding assays were done; namely a competition bind-
ing assay and a direct binding assay. In the first, α4β7 
transfected 293T cells (1 × 105 cells/ml) were incubated 
in the presence or absence of the Act-1 mAb (targets the 
α4β7 dimer) obtained from the NIH AIDS Research and 
Reference Reagent Program or the HP2/1 mAb (Beck-
man Coulter, France) which targets the α4 subunit only, 
for 15 min followed by the addition of the either IECs or 
IMCs for 25 min. Cells were stained as above. Binding to 
α4β7 was defined as the percentage difference between 
the median fluorescence intensity (MFI) of α4-PE and 
β7-FITC of α4β7-transfected cells without an inhibitory 
mAb or virus and the MFI α4β7-transfected cells with 
an inhibitory mAb or virus. The direct binding assay was 
carried out in a similar way except that the cell-virus 
complexes were stained for p24-FITC (KC57, Beckman 
Coulter) and the percentage p24 positive cells gated on 
single live 293T cells were compared between 293T 
untransfected (background) and α4β7  transfected 293T 
cells as a representation of bound virus.
α4β7 mediated virus replication inhibition assay
ATRA-treated CD4+ T lymphocytes (25  μl of 4  ×  106 
cells/ml) from a responder individual were either incu-
bated with 25 μl of media (virus control), 10 μg/ml anti-
CD4 monoclonal antibody (positive control), 275  pM 
inhibiting monoclonal antibody HP2/1 (targeting α4 sub-
unit) or 2.2 pM Act-1 (targets α4β7) for an hour at 37°C at 
5% CO2. Both HP2/1 and Act-1 mAb concentrations were 
optimised by titration in the α4β7-mediated virus capture 
inhibition assay, noting the concentration at which effec-
tiveness of blocking viral replication was highest. 100 μl 
containing 25 TCID50 of IECs and IMCs were incubated 
for 2  h in triplicate with the cells in a 96-well plate, fol-
lowed by two washes with fresh IL-2 media (5% IL-2 at 
200 U/ml, 20% FBS and RPMI media) at 1,200 g for 5 min 
at 25°C. 100 µl of culture supernatant was harvested every 
2 days without disturbing the cells for a period of 10 days 
with removed volume replaced with fresh IL-2 media. 
Table 1 Mutations introduced into the α4β7 binding motif 
of T/F viruses
a Introduced mutations are in italics.
Individual Type α4β7 binding motifa IEC
CAP225 T/F Wild type SDI ✓
Mutant LDI Did not grow
CAP88 T/F Wild type PDI ✓
Mutant LDI Did not grow
CAP200 T/F Wild type SDV ✓
Mutant LDI Did not grow
CAP8 T/F Wild type LDI ✓
Mutant PDI ✓
CAP256 T/F Wild type LDL ✓
Mutant SDI ✓
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Collected supernatants were lysed using 1.25% Empigen/
TBS solution and stored at 4°C before assessing p24 levels 
by ELISA. Percentage dependency on α4β7 was calculated 
as the percentage of difference in p24 between untreated 
samples (virus control) and p24 on samples treated with 
HP2/1 or Act-1 relative to untreated controls at the expo-
nential growth phase of the latter. These single points 
were unique for each virus based on steepness of the gra-
dient of the kinetic growth curve.
Cytokine measurements in CVLs and plasma
CVLs (10  ml sterile saline) for cytokine measurements 
were collected, centrifuged and supernatants stored 
at −80°C. CVLs were not collected from menstruat-
ing participants. Blood was collected by venepuncture 
into acetate citrate dextran vacutainer tubes, plasma 
isolated and stored at −80°C. CVLs were pre-filtered 
by centrifugation using 0.2  μm cellulose acetate filters 
(Sigma, USA). The concentrations of 32 cytokines were 
measured using LINCOplex Human Cytokine and High 
Sensitivity Human Cytokine kits (LINCO Research, 
USA). Human Cytokine LINCOplex kits included Epi-
dermal growth factor (EGF), eotaxin/CCL11, fractalkine/
CX3CL1, G-CSF, IFN-α, IL-1α, IL-1Ra, IL-12p40, IL-15, 
IL-17, IFN-γ-induced protein (IP)-10/CXCL10, MCP-1/
CCL2, MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, 
sCD40L, soluble IL-2 receptor α (sIL-2Rα), transforming 
growth factor (TGF)-α and vascular endothelial growth 
factor (VEGF). Thirteen cytokines were measured in 
CVL and plasma using High Sensitivity LINCOplex kits: 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-10, 
IL-12p70, IL-13, GM-CSF, IFN-γ and TNF-α. The lower 
limit of detection of these kits ranged between 0.01 and 
27.65  pg/ml for each of the cytokines. Data was col-
lected using a Bio-Plex™ Suspension Array Reader (Bio-
Rad Laboratories Inc®) and a 5 PL regression formula 
was used to calculate cytokine concentrations from the 
standard curves (BIO-Plex™ manager software version 4). 
IFN-α and MIP-3α were measured in CVLs using ELISA 
(R&D Systems). Cytokine concentrations below the assay 
lower limit of detection were reported as the mid-point 
between the lowest concentrations measured for each 
cytokine and zero.
Statistical analysis
Paired data with only two groups were assessed by paired 
t test or Wilcoxon matched pairs signed rank test, and in 
groups with three or more sets by the repeated measures 
one way ANOVA with pairwise comparisons adjusted for 
multiple comparisons using Tukey’s method. Unpaired 
data were assessed for significance by the Mann–Whit-
ney test, or the one way ANOVA and the Fisher exact 
test was used to determine the significance of categorical 
groupings. While Spearman’s correlation was used to 
assess linear correlations, correlations were adjusted for 
multiple comparisons using a false discovery rate (FDR) 
step down procedure (STATA version 12, StataCorp, Col-
lege Station, TX, USA). A mixed linear model was fitted 
to assess significance in cases where there were multiple 
comparisons with repeated measures and were corrected 
for duration of infection. Observations of p < 0.05 were 
defined as significant. Statistics and graphs were done 
with GraphPad Prism 5 and STATA 12.
Additional files
Additional file 1: α4β7‑virus binding assays. (A) α4β7 expressed on 
transfected 293T cells (red) and not on the surface of untransfected 293T 
cells (black) confirmed by flow cytometry were used for direct binding 
and competition assays. (B) Infectious viruses represented by p24‑FITC 
MFI bound to α4β7 transfected 293T cells shown in red but not to 
untransfected 293 cells shown in black, representative of 4 independent 
experiments. (C) Viral attachment of CAP88 T/F in the presence of HP2/1 
and Act‑1 was inhibited in the p24 direct binding assay (red and blue 
respectively), representative of 5 independent experiments.
Additional file 2: IECs and IMCs show similar binding to and depend‑
ence on α4β7 for replication. IECs and IMCs of CAP210 T/F and CAP239 
T/F bound to α4β7 at similar levels as defined by (A) p24 binding assay 
where the dashed line represents IMC binding and the solid line repre‑
sents IEC binding and (B) the competition assay. SF162 IEC and IMC also 
bound similarly see Figure 1A. (C) All three viruses showed no differences 
between their IECs and respective IMCs in dependence on α4β7 for rep‑
lication. All results are representative of three experiments with error bars 
representing SEM. No differences were significant by the paired t test.
Additional file 3: Characterisation of a responder and non‑responder to 
ATRA treatment. CD4 cells were treated with ATRA for 6 days and stained for 
α4 and β7. An example of a non‑responder is shown in A and a responder in 
B with an increase in the percentage of cells with α4 and β7 co‑expression.
Additional file 4: Titration of α4β7 inhibitors for maximal inhibition of viral 
replication. (A) A decreasing shift in PE florescence relative to the experimen‑
tal control (ATRA treated CD4 + T cells alone shown in black); is indicated in 
a dose‑dependent manner between 0.0022‑30 nM (i) HP2/1 and (ii) Act‑1 
concentrations (red and blue graduations respectively). All samples were 
gated on single live CD4 + T lymphocytes. (B) Change in median fluorescent 
intensity (MFI) with the 30 nM being the most saturating concentration for 
blocking of the integrin by both mAbs. Both A and B are representative of 
four repeated experiments, with the bars showing the mean and error bars, 
the SEM. (C) The same ATRA activated responders were infected with a T/F 
virus CAP88.2.00.17‑5A and incubated with (i) HP2/1 and (ii) Act‑1 between 
0.0022‑30 nM (red and blue graduations respectively) and monitored over 
10 days by p24‑ELISA. The virus control (no inhibitory mAb) is shown in black 
and the infectivity control shown in grey. The optimum concentration for 
viral inhibition by HP2/1 is 0.275 nM and Act‑1 is 2.2 pM, while the viral rep‑
lication is significantly upregulated at 30 nM in both cases. These results are 
representative of five independent experiments using 3 donors, with error 
bars indicating the SEM and points, the mean of three replicates.
Additional file 5: α4β7 mediated virus capture inhibition assay for all 60 
IECs. Virus growth kinetic curves of CAP8, 88, 177, 200, 206, 210, 225, 239, 
244, 255 and 256 viruses done in triplicate; in the presence or absence of 
HP2/1 mAb (red), Act‑1 mAb (blue) or CD4 mAb (grey) demonstrate their 
inhibitory effect on the replication of T/F, early and chronic clones. Data 
are representative of two independent experiments, with the curves rep‑
resentative of the mean p24 readings and error bars indicating the SEM. 
The longitudinal samples including a T/F from the 3 individuals included 
in Figure 2 are indicated by an asterisk.
Additional file 6: Characteristics of IECs used in this study.
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